Published on
June 16, 2026
- 10:00 GMT
GreenSpace Labs Reports Positive Phase 2 Pilot Data for CBD-Based IBS Therapy GSL-01-001
Clinical-stage company targets 2028–2029 IBS patent cliff with mechanism-distinct cannabinoid approach MIDDLETOWN, RI, UNITED STATES, June 16, 2026 /EINPresswire.com/ -- GreenSpace Labs, Inc. (GSL), a clinical-stage pharmaceutical company developing …
Distribution channels:
Healthcare & Pharmaceuticals Industry
...
